The evolving landscape of pediatric hepatology: key updates and future directions.

IF 2.5 3区医学 Q2 PEDIATRICS

Current opinion in pediatrics Pub Date : 2025-10-01 Epub Date: 2025-07-30 DOI:10.1097/MOP.0000000000001489

Paul Lu, Nadia Ovchinsky, Dana Goldner

{"title":"The evolving landscape of pediatric hepatology: key updates and future directions.","authors":"Paul Lu, Nadia Ovchinsky, Dana Goldner","doi":"10.1097/MOP.0000000000001489","DOIUrl":null,"url":null,"abstract":"Purpose of review: To provide an update of recent advancements in pediatric hepatology, highlighting new diagnostic criteria, emerging therapeutic options, and molecular insights into liver diseases which are reshaping clinical practice and guiding future research.Recent findings: Nonalcoholic fatty liver disease (NAFLD) has been redefned as metabolic dysfunction-associated steatotic liver disease (MASLD), reflecting an improved understanding of its underlying pathophysiology. Advances in immunophenotyping have identified activated T-cell hepatitis as a significant contributor to indeterminate pediatric acute liver failure. Additionally, the introduction of ileal bile acid transporter (IBAT) inhibitors marks a transformative shift in the management of pediatric cholestatic diseases including Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), offering improved growth, quality of life, and native liver survival.Summary: Recent developments in pediatric hepatology are changing how liver diseases are approached in clinical practice. Evolving disease classifications, expanded use of genetic and immunologic profiling, and the introduction of novel therapies mark a shift toward more individualized care. Ongoing research is needed to evaluate long-term outcomes and ensure that these advances translate into durable improvements for children with liver disease.","PeriodicalId":10985,"journal":{"name":"Current opinion in pediatrics","volume":" ","pages":"457-465"},"PeriodicalIF":2.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOP.0000000000001489","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To provide an update of recent advancements in pediatric hepatology, highlighting new diagnostic criteria, emerging therapeutic options, and molecular insights into liver diseases which are reshaping clinical practice and guiding future research.

Recent findings: Nonalcoholic fatty liver disease (NAFLD) has been redefned as metabolic dysfunction-associated steatotic liver disease (MASLD), reflecting an improved understanding of its underlying pathophysiology. Advances in immunophenotyping have identified activated T-cell hepatitis as a significant contributor to indeterminate pediatric acute liver failure. Additionally, the introduction of ileal bile acid transporter (IBAT) inhibitors marks a transformative shift in the management of pediatric cholestatic diseases including Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), offering improved growth, quality of life, and native liver survival.

Summary: Recent developments in pediatric hepatology are changing how liver diseases are approached in clinical practice. Evolving disease classifications, expanded use of genetic and immunologic profiling, and the introduction of novel therapies mark a shift toward more individualized care. Ongoing research is needed to evaluate long-term outcomes and ensure that these advances translate into durable improvements for children with liver disease.

查看原文本刊更多论文

儿科肝病学的发展前景：关键的更新和未来的方向。

综述的目的：提供儿科肝病学的最新进展，强调新的诊断标准，新兴的治疗方案，以及肝脏疾病的分子见解，这些正在重塑临床实践并指导未来的研究。最近的研究发现：非酒精性脂肪性肝病（NAFLD）被重新定义为代谢功能障碍相关的脂肪性肝病（MASLD），这反映了对其潜在病理生理学的更好理解。免疫分型的进展已经确定活化t细胞肝炎是儿童急性肝衰竭的一个重要因素。此外，回肠胆汁酸转运蛋白（IBAT）抑制剂的引入标志着儿童胆汁淤积症（包括Alagille综合征和进行性家族性肝内胆汁淤积症（PFIC））管理的革命性转变，可改善生长、生活质量和原生肝脏存活率。摘要：儿科肝病学的最新进展正在改变肝病在临床实践中的治疗方式。不断发展的疾病分类，遗传和免疫谱分析的扩大使用，以及新疗法的引入标志着向更加个性化的护理的转变。需要进行持续的研究来评估长期结果，并确保这些进展转化为肝病儿童的持久改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in pediatrics 医学-小儿科

CiteScore

6.20

自引率

0.00%

发文量

184

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Pediatrics is a reader-friendly resource which allows the reader to keep up-to-date with the most important advances in the pediatric field. Each issue of Current Opinion in Pediatrics contains three main sections delivering a diverse and comprehensive cover of all key issues related to pediatrics; including genetics, therapeutics and toxicology, adolescent medicine, neonatology and perinatology, and orthopedics. Unique to Current Opinion in Pediatrics is the office pediatrics section which appears in every issue and covers popular topics such as fever, immunization and ADHD. Current Opinion in Pediatrics is an indispensable journal for the busy clinician, researcher or student.